ETON Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$54.75median target· current $46.42 (+17.9%)3 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 52.63
EPS (TTM)$-0.06-12.6% YoY
Profit margin-1.7%HEALTHCARE
Market cap$1.27BSmall cap
Valuation
- Forward P/E
- 52.63
- PEG ratio
- —
- P/B
- 41.52
- P/S (TTM)
- 14.63
- EV/EBITDA
- 206.79
Profitability & growth
- ROE (TTM)
- -5.4%
- Operating margin
- 11.4%
- Revenue growth YoY
- 40.4%
- Dividend yield
- —
- Beta
- 0.86
Last earnings
May 14, 2026 · Estimate $0.14 · Reported $0.14
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Eton Pharmaceuticals Inc
Company profileEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 21925 W. FIELD PARKWAY, DEER PARK, IL
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$1.27B
Shares outstanding$27.4M
52W high$50.18
52W low$13.98
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent